Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function
- PDF / 1,191,210 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 89 Downloads / 187 Views
ORIGINAL ARTICLE
Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3‑year post‑marketing surveillance study (STELLA‑LONG TERM) Kazuyuki Tobe1 · Hiroshi Maegawa2 · Ichiro Nakamura3 · Satoshi Uno4 Received: 21 August 2020 / Accepted: 12 October 2020 © The Japan Diabetes Society 2020
Abstract STELLA-LONG TERM, a 3-year post-marketing surveillance study, evaluated the safety and effectiveness of the sodiumglucose cotransporter 2 inhibitor ipragliflozin in Japanese type 2 diabetes mellitus (T2DM) patients. Final results in the safety (n = 6697) and effectiveness populations (n = 5625) were analyzed by stratifying patients by baseline estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) into four subgroups (≥ 90, 60 to
Data Loading...
